Research and Clinical Trials

Brief Description  
The purpose of this study is to evaluate the efficacy and safety of V212 in adult patients who have either a malignancy of the blood or a solid tumor malignancy.
Who may be Eligible  

Inclusion Criteria:
  • Patient has been diagnosed with a solid tumor or hematologic malignancy AND is not likely to undergo hematopoietic cell transplant and meets one of the criteria specified below.
    1. Is 18 years of age or older and is receiving a cytotoxic or immunosuppressive chemotherapy regimen that does not include rituximab.
    2. Is 50 years of age or older with a hematologic malignancy, not in remission, regardless of whether the patient is or is not receiving chemotherapy.
    3. Is not receiving and not expected to require rituximab therapy beginning 3 months prior to enrollment through 28 days postvaccination dose 4.
  • Patient has prior history of varicella (chickenpox)
  • Able to understand and complete study questionnaires

Exclusion Criteria:
  • Prior history of Herpes Zoster (shingles) within 1 year of enrollment
  • Prior receipt of any varicella or zoster vaccine
  • Patient is currently receiving or expected to receive long-term antiviral prophylaxis (greater than 4 weeks duration) with activity against herpes simplex virus or cytomegalovirus.
  • Ay live virus vaccine administered or scheduled in the period from 4 weeks prior to Dose 1 through 28 days postvaccination dose 4.
Shingles Vaccine
IRB Number  
Principal Investigator  
Carrizosa, Daniel

For More Information, Contact  Tesa  M, Adams
Phone:  (704) 446-5145  Fax:  (704) 355-1352  
Address:1100 South Tryon Street Suite 220 Charlotte, NC 28203